Masimo Corporation (MASI)
NASDAQ: MASI · Electromedical & Electrotherapeutic Apparatus · Irvine, CA
Our rating: Neutral
First call: Neutral, moderate conviction, at $179.95, moderate conviction, June 10, 2026.
Breaks if: Turn Positive if free cash flow reaches $280M or above on a trailing four-quarter basis within the next 18 months while the GAAP net loss narrows to below $80M, signaling that the non-cash drag is genuinely resolving and growth is beginning to convert to earnings. Turn Cautious if free cash flow falls below $120M on a trailing four-quarter basis at any point in the next 12 months, or if reported revenue growth decelerates to below 5% year-over-year in the next fiscal year disclosed.
Key figures
| Market value | $9.4B |
|---|---|
| Revenue, last 12 months | $1.6B |
| Net income, last 12 months | $76M |
| Free cash flow, last 12 months | $211M |
| Price to earnings | 123.5× |
| Free cash flow yield | 2.2% |
| Dividend yield | 0.0% |
| Operating margin | 19.9% |
| Return on equity | 8.8% |
| Beta to the S&P 500 | 0.97 |
| Volatility, annualized | 44.1% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| April 4, 2026 | $404M | 8.5% | $1.09 | $41M |
| January 3, 2026 | $413M | 12.0% | $1.21 | $53M |
| September 27, 2025 | $372M | 8.2% | $-1.84 | $51M |
| June 28, 2025 | $371M | 7.9% | $0.94 | $66M |
| March 29, 2025 | $372M | 9.5% | $-3.12 | $29M |
| December 28, 2024 | $368M | −264.7% | $-6.43 | $44M |
| September 28, 2024 | $343M | −28.3% | $0.18 | $20M |
| June 29, 2024 | $344M | −24.5% | $0.30 | $71M |
1 ledger entries and 62 corporate events on record. Share price as of June 10, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.